Format

Send to

Choose Destination
Adv Exp Med Biol. 2018;1067:89-108. doi: 10.1007/5584_2017_140.

Circulating Biomarkers in Heart Failure.

Author information

1
Internal Medicine Department, State Medical University of Zaporozhye, Zaporozhye, Ukraine. dr_berezin@mail.ru.

Abstract

Biological markers have served for diagnosis, risk stratification and guided therapy of heart failure (HF). Our knowledge regarding abilities of biomarkers to relate to several pathways of HF pathogenesis and reflect clinical worsening or improvement in the disease is steadily expanding. Although there are numerous clinical guidelines, which clearly diagnosis, prevention and evidence-based treatment of HF, a strategy regarding exclusion of HF, as well as risk stratification of HF, nature evolution of disease is not well established and requires more development. The aim of the chapter is to discuss a role of biomarker-based approaches for more accurate diagnosis, in-depth risk stratification and individual targeting in treatment of patients with HF.

KEYWORDS:

Biomarker guided-therapy; Biomarkers; Heart failure; Prediction; Stratification

PMID:
29392578
DOI:
10.1007/5584_2017_140
[Indexed for MEDLINE]

Supplemental Content

Full text links

Icon for Springer
Loading ...
Support Center